EC Number   |
Application |
Reference |
|---|
    2.1.1.5 | analysis |
synthesis of a series of S-substituted derivatives of homocysteine as potential inhibitors of human recombinant BHMT, some of these compounds are very potent inhibitors, having IC50 values in the nanomolar range |
675300 |
| 2.1.1.5 | food industry |
compared with the prepartum level, overall BHMT expression and enzyme activity increases 0.7-fold and 1.7-fold, respectively, soon after parturition. There is no overall effect of methionine or choline supplementation for BHMT expression or BHMT enzyme activity |
757466 |
| 2.1.1.5 | medicine |
a polymorphisms in betaine-homocysteine S-methyltransferase might be linked to an increased risk for placental abruption |
689005 |
| 2.1.1.5 | medicine |
BHMT1 is a auto-antigen associated with anti-Golgi immune reactivity. Antibodies to BHMT1 were found in four of 80 samples with a Golgi-pattern on indirect immunofluorescence. The antibodies are not associated with a specific clinical condition |
733673 |
| 2.1.1.5 | medicine |
decreased plasma homocysteine in various models of diabetes may be due to enhanced homocysteine removal brought about by a combination of increased transsulfuration of homocysteine to cysteine and increased remethylation of homocysteine to methionine by BHMT |
671232 |
| 2.1.1.5 | medicine |
effect of extrahepatic expression of homo sapiens betaine-homocysteine methyltransferase on alcohol or homocysteine-induced fatty liver is shown in transgenic mice |
684264 |
| 2.1.1.5 | medicine |
in serum from healthy individuals, the median value is 1.83 ng/ml. In serum from patients with acute liver injury, the median value of BHMT is 748.48 ng/ml. The detection range of the ELISA assay is from 1.56 to 100 ng/ml with good sensitivity and specificity. In five acute liver injury cases with time course samples available, BHMT and alanine transaminase both follow the rise and fall temporal pattern with the disease progression. The slopes of BHMT curves are steeper than alanine transaminase curves. In three out of the five cases, BHMT levels peak 1 day earlier than alanine transaminase levels |
733463 |
| 2.1.1.5 | medicine |
methionine-deficient diet produces large increase in enzyme activity |
441242 |
| 2.1.1.5 | medicine |
transient inhibition of BHMT in vivo causes transient hyperhomocysteinemia |
675562 |
| 2.1.1.5 | medicine |
treatment of hepatocytes with homocysteine to follow the impact of hyperhomocysteinemia and concomittant inhibition of betaine-homocysteine S-methyltransferase BHMT. Inhibition and 0.1 mM homocysteine treatment induce only moderate changes in the hepatocyte proteome and secretome, while the changes induced by 2 mM homocysteine treatment are extensive: phosphatidylethanolamine carboxykinase and ornithine aminotransferase are up-regulated about twofold indicating an intervention into metabolism. Cellular proliferation is suspended, secretome composition is changed and signs of apoptosis are discernible. Fibrinogen gamma dimers can be detected and maturation of apolipoprotein A1 fails |
733401 |
